119 related articles for article (PubMed ID: 19862802)
1. Feasibility study of pollen-shape drug carriers in dry powder inhalation.
Hassan MS; Lau R
J Pharm Sci; 2010 Mar; 99(3):1309-21. PubMed ID: 19862802
[TBL] [Abstract][Full Text] [Related]
2. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
Hassan MS; Lau R
Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
[TBL] [Abstract][Full Text] [Related]
3. Inhalation performance of pollen-shape carrier in dry powder formulation: effect of size and surface morphology.
Hassan MS; Lau R
Int J Pharm; 2011 Jul; 413(1-2):93-102. PubMed ID: 21540087
[TBL] [Abstract][Full Text] [Related]
4. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
Zeng XM; Martin GP; Marriott C; Pritchard J
J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
6. Effect of particle shape on dry particle inhalation: study of flowability, aerosolization, and deposition properties.
Hassan MS; Lau RW
AAPS PharmSciTech; 2009; 10(4):1252-62. PubMed ID: 19866362
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress of dry powder inhalation of proteins and peptides].
Zhou JY; Zhang L; Mao SR
Yao Xue Xue Bao; 2015 Jul; 50(7):814-23. PubMed ID: 26552141
[TBL] [Abstract][Full Text] [Related]
8. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary deposition of lactose carriers used in inhalation powders.
Karhu M; Kuikka J; Kauppinen T; Bergström K; Vidgren M
Int J Pharm; 2000 Feb; 196(1):95-103. PubMed ID: 10675711
[TBL] [Abstract][Full Text] [Related]
10. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
[TBL] [Abstract][Full Text] [Related]
11. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
12. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
[TBL] [Abstract][Full Text] [Related]
13. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed.
Iida K; Todo H; Okamoto H; Danjo K; Leuenberger H
Chem Pharm Bull (Tokyo); 2005 Apr; 53(4):431-4. PubMed ID: 15802846
[TBL] [Abstract][Full Text] [Related]
14. Lactose characteristics and the generation of the aerosol.
Pilcer G; Wauthoz N; Amighi K
Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
[TBL] [Abstract][Full Text] [Related]
15. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
16. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
Donovan MJ; Smyth HD
Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
[TBL] [Abstract][Full Text] [Related]
17. Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI.
Harjunen P; Lehto VP; Martimo K; Suihko E; Lankinen T; Paronen P; Järvinen K
Eur J Pharm Sci; 2002 Sep; 16(4-5):313-21. PubMed ID: 12208462
[TBL] [Abstract][Full Text] [Related]
18. Characterisation and functionality of inhalation anhydrous lactose.
Pitchayajittipong C; Price R; Shur J; Kaerger JS; Edge S
Int J Pharm; 2010 May; 390(2):134-41. PubMed ID: 20100552
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
Liang ZL; Wang XH; Ni R; Zhang L; Muenster U; Mao SR
Yao Xue Xue Bao; 2015 Sep; 50(9):1180-5. PubMed ID: 26757557
[TBL] [Abstract][Full Text] [Related]
20. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
